Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset
Aseptika Limited announced that it has been granted a patent in the United States (US) protecting its invention for a test for respiratory infections, designed to be used by patients at home and by clinicians at the bedside of patients in hospitals. This will open up opportunities for the Company to partner with pharmaceutical companies in the US to act as a distributor for the Sputum test.
The Patent granted to Aseptika in the US (Patent US8980566B2), with other worldwide applications taking place under the International Patent Treaty expected to be granted in the near future. The Patent determines the levels of activity of bacteria in the lungs of vulnerable patients with long-term conditions, such as Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and Asthma.
The presence of two very different materials (biomarkers) produced by the bacterium (Pseudomonas aeruginosa) are described, in which the levels of a marker for a bacterial iron scavenging process and levels of a secreted bacterial protein are measured over time. Changes in these concentrations allow levels of bacterial activity to be determined and exacerbations of bacterial infection to be predicted and/or monitored. The methods of the invention may also be used for monitoring effectiveness of antibiotic treatment of lung infection.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
A new mechanism protects against cancer cell migration and neuron hyperexcitability
Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Asterion Raises £355k Funding to Progress Novel Therapies for Hormone Related Diseases
Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase
Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity
Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration
